Country: Canada
Language: English
Source: Health Canada
PERINDOPRIL ERBUMINE
SERVIER CANADA INC
C09AA04
PERINDOPRIL
2MG
TABLET
PERINDOPRIL ERBUMINE 2MG
ORAL
30
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178001; AHFS:
MARKETED
1994-12-31
_ _ _COVERSYL_ _®_ _ (perindopril erbumine) Product Monograph _ _Page 1 of 63_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR COVERSYL® Perindopril erbumine Tablets Tablets, 2 mg, 4 mg and 8 mg, Oral Angiotensin Converting Enzyme Inhibitor Servier Canada Inc. 3224 Avenue Jean-Béraud #270 Laval, Quebec H7T 2S4 Canada Date of Initial Authorization: June 6, 1994 Date of Revision: October 21, 2022 Submission Control Number: 264109 _ _ _COVERSYL_ _®_ _ (perindopril erbumine) Product Monograph _ _Page 2 of 63_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS [10/2022] 7 WARNING AND PRECAUTIONS [10/2022] TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics (< 18 years of age)................................................................................4 1.2 Geriatrics (>65 years of age).................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..............................................................5 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations .........................................................................................5 4.2 Recommended Dose and Dosage Adjustment.......................................................5 4.4 Administration................. Read the complete document